期刊文献+

DNA甲基转移酶在慢性髓系白血病患者的表达及临床意义 被引量:3

Expression and Clinical Significance of DNMT in Patients with Chronic Myeloid Leukemia
在线阅读 下载PDF
导出
摘要 目的:探讨慢性髓系白血病(CML)患者骨髓或外周血单个核细胞DNA甲基转移酶(DNMT)的表达水平及临床意义。方法:应用SYBR Green荧光定量PCR的方法检测94例3个不同时期CML患者及10例正常对照者骨髓或外周血单个核细胞中DNMT mRNA的表达水平。结果:正常对照(NC)组、CML慢性期(CML-CP)、加速期(CML-AP)、急变期(CML-BP)组DNMT1 mRNA的相对表达水平分别为1.45±0.22、1.83±0.63、2.95±0.87、3.24±1.39,CML-CP组患者与NC组比较表达水平差异统计学意义(P=0.28);CML疾病进展期包括(CML-AP和CML-BP)较NC和CML-CP组表达水平显著增高(P<0.01);CML-AP与CML-BP相比表达水平无统计学差异(P=0.336)。NC、CML-CP、CML-AP、CML-BP组DNMT3a mRNA的相对表达水平分别为1.29±0.34、1.34±0.46、2.33±1.05、3.18±1.23。CML-CP组患者与NC组比较表达水平无统计学差异(P=0.844);CML疾病进展期较NC组和CML-CP组表达水平显著增高(P<0.05);CML-AP与CML-BP相比表达水平无统计学差异(P=0.304)。NC、CML-CP、CML-AP、CML-BP组DNMT3b mRNA的相对表达水平分别为1.37±0.31、16.41±22.50、9.36±5.50、12.17±13.44,在CML患者较在NC组表达水平显著增高(P<0.05)。CML患者各期之间比较无统计学差异(P>0.05)。结论:疾病进展期CML患者中DNMT mRNA表达增高,DNMT mRNA表达水平与CML疾病进展相关。 Objective:To investigate the expression and clinical significance of DNA methyltransferases(DNMT)mRNA in patients with chronic myeloid leukemia(CML).Methods:The expression levels of DNMT mRNA in mononucllear cells(MNC) of bone marrow or in peripheral blood of 93 CML patients in 3 different phases and 10 normal controls(NC) were detected by SYBR Green flurescent quatitative PCR.Results:The relative expression levels of DNMT1 mRNA in NC,chronic phase CML(CML-CP),accelerated phase(CML-AP) and blastic phase(CML-BP)were 1.45 ± 0.22,1.83 ± 0.63,2.95 ± 0.87 and 3.24 ± 1.39 resectively.The expression of DNMT1 mRNA showed no statistically significant difference between CML-CP and NC(P = 0.28).The expression of DNMT1 mRNA in advanced stages(including CML-AP and CML-BP) of CML obviously increased in comparison with CML-CP and NC(P <0.05).The expression of DNMT1 mRNA in CML-AP was not significantly different from that in CML-BP(P = 0.336).The relative expression levels of DNMT3 a mRNA in NC,CML-CP,CML-AP and CML-BP groups were 1.29 ±0.34,1.34 ± 0.46,2.33 ± 1.05 and 3.18 ± 1.23 resectively.And the expression levels of DNMT3 a mRNA were not statistically significantly different between CML-CP and N C(P = 0.844).The results showed that the expression of DNMT3 a mRNA in the advanced phase of CML significantly increased in comparison with that in CML-CP and NC(P <0.05).Meanwhile,the expression of DNMT3α mRNA in CML-AP was not different from that in CML-BP(P =0.304).The relative expression levels of DNMT3 b mRNA in NC,CML-CP,CML-AP and CML-BP groups were 1.37 ± 0.31,16.41 ±22.50,9.36 ±5.50 and 12.17 ± 13.44 resectively.It was also found that the level of DNMT3 b mRNA in CML significantly increased in comparison with NC(P < 0.05),and that the between the 3 different phase of CML was not statistically significantly different(P > 0.05).Conclusion:The expression of DNMT mRNA increases in advanced CML as compared with normal controls and CML-CP,and the increased levels of DNMT mRNA probably correlate with disease progression in CML.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2015年第6期1547-1550,共4页 Journal of Experimental Hematology
基金 河北省医学研究课题计划项目ZD2014090
关键词 DNA甲基转移酶 慢性 髓系 白血病 疾病进展 DNMTs chronic myelogenous leukemia disease progression
  • 相关文献

参考文献11

  • 1Viré Emmanuelle,Brenner Carmen,Deplus Rachel,Blanchon Lo?c,Fraga Mario,Didelot Céline,Morey Lluis,Van Eynde Aleyde,Bernard David,Vanderwinden Jean-Marie,Bollen Mathieu,Esteller Manel,Di Croce Luciano,de Launoit Yvan,Fuks Fran?ois.The Polycomb group protein EZH2 directly controls DNA methylation. Nature . 2005
  • 2Ruo-Kai Lin,Chiu-Yi Wu,Jer-Wei Chang,Li-Jung Juan,Han-Shui Hsu,Chih-Yi Chen,Yun-Yueh Lu,Yen-An Tang,Yi-Chieh Yang,Pan-Chyr Yang,Yi-Ching Wa.Dysregulation of p53/Sp1 Control Leads to DNA Methyltransferase-1 Overexpression in Lung Cancer. Cancer Research . 2010
  • 3Handa H,Kaneko A,Suda I,et al.Interrelationship Of c-Myc,Micro RNA 29 and 34 Families,DNA methyltransferases and Methylation In Acute Myeloid Leukemia. Blood . 2013
  • 4吴圣豪,郑翠苹,徐杰,蔡小平,石岳坚.骨髓DNA甲基转移酶基因在急性髓系白血病患者的表达及意义[J].中国实验血液学杂志,2012,20(5):1063-1065. 被引量:4
  • 5陈存华,杨俊鹏.恶性血液病去甲基化治疗的研究进展[J].中国实验血液学杂志,2009,17(5):1394-1398. 被引量:3
  • 6Michele Baccarani,Michael W. Deininger,Gianantonio Rosti,Andreas Hochhaus,Simona Soverini,Jane F. Apperley,Francisco Cervantes,Richard E. Clark,Jorge E. Cortes,Fran?ois Guilhot,Henrik Hjorth-Hansen,Timothy P. Hughes,Hagop M. Kantarjian,Dong-Wook Kim,Richard A. Larson,Jeffrey H. Lipton,Fran?ois-Xavier Mahon,Giovanni Martinelli,Jiri Mayer,Martin C. Müller,Dietger Niederwieser,Fabrizio Pane,Jerald P. Radich,Philippe Rousselot,Giuseppe Saglio,Susanne Sau?ele,Charles Schiffer,Richard S.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013[J]. Blood . 2013 (6)
  • 7Renata ZofiaJurkowska,Tomasz PiotrJurkowski,AlbertJeltsch.Structure and Function of Mammalian DNA Methyltransferases[J].ChemBioChem.2011(2)
  • 8Perrotti, Danilo,Jamieson, Catriona,Goldman, John,Skorski, Tomasz.??Chronic myeloid leukemia: mechanisms of blastic transformation(J)Journal of Clinical Investigation . 2010 (7)
  • 9Radich JP,Dai H,Mao M,et al.Gene expression changes associat-ed with progression and response in chronic myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America . 2006
  • 10Mizuno S,Chijiwa T,Okamura T,Akashi K,Fukumaki Y,Niho Y,Sasaki H.Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood . 2001

二级参考文献15

  • 1乔淑凯,徐世荣,郭晓楠,王颖.急性白血病患者DNA甲基转移酶基因的表达其及临床意义[J].中国实验血液学杂志,2005,13(2):260-265. 被引量:6
  • 2LiYu,ChunhuiLiu,JeffVandeusen,BrianBecknell,ZunyanDai,Yue-ZhongWu,AparnaRaval,Te-HuiLiu,WeiDing,CharleneMao,ShujunLiu,LauraTSmith,StephenLee,LauraRassenti,GuidoMarcucci,JohnByrd,MichaelACaligiuri,ChristophPlass.Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia[J].中国生物学文摘,2005,19(4):109-118. 被引量:80
  • 3沈建箴,周华蓉.去甲基化在治疗恶性血液病中的研究[J].中华内科杂志,2006,45(5):355-356. 被引量:8
  • 4Liu S, Liu Z, Xie Z, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Spl/NF-KB-dependent DNAmethyltransferase activity in acute myeloid leukemia. Blood, 2008 ; 111 (4) : 2364 - 2373.
  • 5Snbramanyam D, Belair CD, Barry-Holson KQ, et al. PML-RARct and DNMT13al cooperate in vivo to promote acute promyelocytic leukemia. Cancer Res, 2010 ; 70(21 ) :8792 - 8801.
  • 6Melki JR, Warnecke P, Vincent PC, et al. Increased DNA methyltransferase expression in leukemia. Leukemia, 1998;12(3 ) : 311 -316.
  • 7Ghoshal K, Bai S. DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc) ,2007 ; 43 ( 6 ) :395 - 422.
  • 8Liu S, Shen T, Huynh L, et al. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res, 2005 ; 65 (4) : 1277 - 1284.
  • 9Jung Y, Park J, Kim TY, et al. Potential advantages of DNA methyltransferases-1 (DNMT11)-targeted inhibition for cancer thera!ay. J Mol Med. 2007: 85(10) :1137 - 1148.
  • 10Nakayama M,Wada M, Harada T, et al. Hypomethylation status of CpG site at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemia. Blood, 1998 ; 92 ( 11 ) : 4296 - 4307.

共引文献11

同被引文献20

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部